combination therapy with glp-1 receptor agonist and sglt2 inhibitor A retrospective analysis of agonists inhibitors versus SGLT2 monotherapy in patients with MASLD GLP-1-based therapies for type 2

Glucagon-like peptide-1 1 (GLP-1) is an incretin hormone secreted by the intestinal epithelial endocrine L-cells 2 in response to food

Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on -cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis

Weight Loss Results: Clinical Data and Real-World Outcomes Clinical trials show substantial differences in weight loss between these medications

(2020, March 10)

In SUSTAIN-6 trial similar effects in MACE risk reduction, glycemic control and hypoglycemia rates were observed in patients receiving 0.5 mg semaglutide once weekly and in those receiving 1 mg once weekly (43)

This is dangerous because people with eating disorders are already at risk for nutritional deficiencies and disordered relationships with food